CONNECT WITH US
HealthTech

HealthTech

CAR T-cell therapy shows promise for patients with lupus

Medical Xpress logo

Published on

Add as a preferred source on Google
CAR T-cell therapy shows promise for patients with lupus

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

For patients with systemic lupus erythematosus (SLE), chimeric antigen receptor T-cell (CAR T-cell) therapy is associated with consistent reductions in disease activity, according to research presented at the annual meeting of the American College of Rheumatology (ACR Convergence 2026), held from Nov. 6 to 11 in Orlando, Florida.

Alberto Nordmann-Gomes, M.D., from Boston University Medical Center, and colleagues conducted a systematic review of all clinical studies assessing safety and/or efficacy outcomes for CAR T-cell therapy in SLE. Data were included from 31 studies, with a combined population of 243 participants. All studies included patients with refractory SLE who had failed two or more immunosuppressants.

The researchers found 12 patients (5%) reported immune effector cell-associated neurotoxicity syndrome and 11 (5%) developed severe infections. Twenty-two patients (9%) reported prolonged hematologic toxicity. The mean SLE disease activity index (SLEDAI) decreased from 13.0 at baseline to 5.8 after one month, 3.1 after three months and 2.2 after six months of therapy.

35, respectively). 33).



Source link

Disclaimer

We strive to uphold the highest ethical standards in all of our reporting and coverage. We TheMorningPulse.fyi want to be transparent with our readers about any potential conflicts of interest that may arise in our work. It's possible that some of the investors we feature may have connections to other businesses, including competitors or companies we write about. However, we want to assure our readers that this will not have any impact on the integrity or impartiality of our reporting. We are committed to delivering accurate, unbiased news and information to our audience, and we will continue to uphold our ethics and principles in all of our work. Thank you for your trust and support.